Skip to main content
SpringerLink
Log in

Prevention and Treatment of Diabetic Nephropathy in Older Patients

  • Therapy in Practice
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Renal disease in older diabetic patients is costly in terms of morbidity, mortality and expenditure. Therefore, prevention and treatment of diabetic nephropathy has become a prominent goal in the treatment of patients with diabetes mellitus. Preventive treatment should begin no later than at the stage of microalbuminuria, and regular screening for microalbuminuria is recommended for all patients with diabetes, irrespective of age.

Improved metabolic control has been demonstrated to lower urinary albumin excretion. Target glycosylated haemoglobin levels should be below 7%, or 1% above the upper limit of normal of non-diabetic subjects. The use of an intensified treatment regimen is recommended. Insulin therapy has no adverse effects on renal indexes.

To preserve renal function in older diabetic patients, blood pressure should be kept at or below 130/80mm Hg. Treatment with ACE inhibitors or angiotensin II receptor antagonists (angiotensin II receptor blockers; ARBs) is superior to other pharmacological therapy, and should be initiated as first-line treatment. Most of the calcium channel antagonists have been found to increase or to have no effect on microalbuminuria despite blood pressure reduction. Moreover, there is substantial controversy as to whether they may be associated with increased cardiovascular morbidity. Non-dihydropyridine derivatives and calcium channel antagonists, such as nitrendipine, may be nephroprotective and have favourable effects on patients outcomes.

A renoprotective action of diuretics may be confined to indapamide. Although β-adrenoreceptor blockers are effective antihypertensive agents, they may not adequately preserve kidney function in older diabetic patients. However, as add-on treatment to ACE inhibitors or ARBs, they are particularly beneficial in nephropathic patients at risk of cardiovascular disease or with arrhythmias, in whom they may prove life-saving.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Diabetes Association. Screening for diabetes. Diabetes Care 2002; 25Suppl. 1: S21–4

    Google Scholar 

  2. Singh I, Marshall MC. Diabetes mellitus in the elderly. Endocrinol Metab Clin North Am 1995; 24: 255–72

    PubMed  CAS  Google Scholar 

  3. Jungmann E. Chemoprophylaxis of diabetic nephropathy in the elderly. Drugs Aging 1996; 9: 449–56

    Article  PubMed  CAS  Google Scholar 

  4. Remuzzi G, Schieppati A, Ruggenenti P. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002; 346: 1145–51

    Article  PubMed  Google Scholar 

  5. Ritz E, Rychlik I, Locatelli F, et al. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimension. Am J Kidney Dis 1999; 34: 795–808

    Article  PubMed  CAS  Google Scholar 

  6. American Diabetes Association. Diabetic nephropathy. Diabetes Care 2002; 25Suppl. 1: S85–93

    Google Scholar 

  7. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002; 25Suppl. 1: S33–49

    Google Scholar 

  8. Ibrahim HAA, Vora JP. Diabetic nephropathy. Baillieres Clin Endocrin Metab 1999; 13: 239–64

    Article  CAS  Google Scholar 

  9. Skyler JS. Microvascular complications. Endocrinol Metab Clin North Am 2001; 30: 833–56

    Article  PubMed  CAS  Google Scholar 

  10. Thomas SM. What should we do about microalbuminuria? In: Gill GV, Pickup JC, Williams G, editors. Difficult diabetes. Oxford: Blackwell Science, 2001: 53–70

    Chapter  Google Scholar 

  11. Valmadrid CT, Klein R, Moss SC, et al. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000; 160: 1093–100

    Article  PubMed  CAS  Google Scholar 

  12. Jungmann E, Graeber S, Scherberich J, et al. The role of rising blood pressure and of human atrial natriuretic peptide in the pathogenesis of diabetic nephropathy in patients with type 1 diabetes mellitus [in German]. Nieren- und Hochdruckkrh 1993; 22: 301–4

    Google Scholar 

  13. Jungmann E, Carlberg C, Schallmayer M, et al. Albuminuria in patients with type 2 diabetes mellitus: impact of blood pressure and metabolic control [in German]. Med Klin 1995; 90: 383–9

    CAS  Google Scholar 

  14. Zelmanovitz T, Paggi A, Gross JL, et al. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care 1997; 20: 516–9

    Article  PubMed  CAS  Google Scholar 

  15. Adler SG, Kang SW, Feld S, et al. Glomerular mRNAs in human type 1 diabetes: biochemical evidence for microalbuminuria as a manifestation of diabetic nephropathy. Kidney Int 2001; 60: 2330–6

    Article  PubMed  CAS  Google Scholar 

  16. Forsblom CM, Groop PH, Ekstrand A, et al. Predictive value of microalbuminuria in patients with insulin-dependent diabetes of long duration. BMJ 1992; 305: 1051–3

    Article  PubMed  CAS  Google Scholar 

  17. Allen KV, Walker JD. The prognostic significance of abnormal urinary albumin excretion in long-duration type 1 diabetes [abstract]. Diabetes 2002; 51Suppl. 2: A37

    Google Scholar 

  18. Lurbe E, Redon J, Kesani A, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002; 347: 797–805

    Article  PubMed  CAS  Google Scholar 

  19. Jungmann E. Excretion of tubular markers in diabetic nephropathy: impact of conversion-enzyme inhibition [in German]. Dtsch Med Wochenschr 1995; 120: 82–3

    PubMed  CAS  Google Scholar 

  20. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes 2000; 49: 1399–408

    Article  PubMed  CAS  Google Scholar 

  21. Gerstein HC, Mann FE, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421–6

    Article  PubMed  CAS  Google Scholar 

  22. Gall MA, Borch-Johnsen K, Hougaard P, et al. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995; 44: 1303–9

    Article  PubMed  CAS  Google Scholar 

  23. The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995; 47: 1703–20

    Article  Google Scholar 

  24. Stratton IM, Adler AI, Neil HAW, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405–12

    Article  PubMed  CAS  Google Scholar 

  25. Holman RR, Turner RC, Cull CA, et al. A randomised double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UKPDS 44). Diabetes Care 1999; 22: 960–4

    Article  PubMed  CAS  Google Scholar 

  26. American Diabetes Association. Implications of the UKPDS. Diabetes Care 2002; 25Suppl. 1: S28–32

    Google Scholar 

  27. Nakamura T, Ushiyama C, Shimada N, et al. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-I and albumin excretion in diabetes patients. J Diabetes Complications 2000; 14: 250–4

    Article  PubMed  CAS  Google Scholar 

  28. Shichiri M, Ohkubo Y, Kishikawa H, et al. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23Suppl. 2: B21–9

    PubMed  Google Scholar 

  29. Jungmann E, Helling T, Jungmann G. Persistent improvement of metabolic control in type 2 diabetes mellitus enabled by intensive insulin treatment using insulin lispro [abstract]. Diabetologia 2000; 43Suppl. 1: A199

    Google Scholar 

  30. Lalau JD, Guerin C, Lacroix C, et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 1995; 18: 779–84

    Article  PubMed  CAS  Google Scholar 

  31. Ruggenenti P, Dodesini AR, Flores C, et al. Insulin lispro is better than regular insulin in limiting post-prandial hyperglycaemia and fully prevents meal-induced hyperfiltration in type 2 diabetics with overt nephropathy [abstract]. Diabetes 2002; 51Suppl. 2: A191

    Google Scholar 

  32. Cooper MA. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 325: 213–9

    Article  Google Scholar 

  33. Ribstein J, du Cailar G, Mimran A. Combined renal effects of overweight and hypertension. Hypertension 1995; 26: 610–5

    Article  PubMed  CAS  Google Scholar 

  34. Jungmann E, Jungmann G. Hypertension, obesity and metabolic control, and microalbuminuria [in German]. J Hyperten 1999; 3: 21–6

    Google Scholar 

  35. Dodson PM, Beevers M, Hallworth R, et al. Sodium restriction and blood pressure in hypertensive type 2 diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ 1989; 298: 227–30

    Article  PubMed  CAS  Google Scholar 

  36. Jungmann E. Diabetic sodium retention [in German]. Nieren- und Hochdruckkrh 1992; 21: 709–15

    Google Scholar 

  37. Scott LJ, Warram JH, Hanna LS, et al. A nonlinear effect of hyperglycaemia and current cigarette smoking are major determinants of the onset of microalbuminuria in type 1 diabetes. Diabetes 2001; 50: 2842–9

    Article  PubMed  CAS  Google Scholar 

  38. Nelson RG, Pettitt DJ, Baird HR, et al. Pre-diabetic blood pressure predicts urinary albumin excretion after the onset of type 2 diabetes mellitus in Pima Indians. Diabetologia 1993; 36: 998–1001

    Article  PubMed  CAS  Google Scholar 

  39. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36: 646–61

    Article  PubMed  CAS  Google Scholar 

  40. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62

    Article  PubMed  CAS  Google Scholar 

  41. Adler AI, Stratton IM, Neil AW, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412–9

    Article  PubMed  CAS  Google Scholar 

  42. Orchard TJ, Kuller LH, Forrest KYZ, et al. Lipid and blood pressure treatment goals for type 1 diabetes. Diabetes Care 2001; 24: 1053–9

    Article  PubMed  CAS  Google Scholar 

  43. Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086–97

    Article  PubMed  Google Scholar 

  44. Lewis JB, Berl T, Bain RP, et al. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Am J Kidney Dis 1999; 34: 809–17

    Article  PubMed  CAS  Google Scholar 

  45. Ravid M, Savin H, Jutrin I, et al. Long-term stabilising effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type 2 diabetic patients. Ann Intern Med 1993; 118: 577–81

    PubMed  CAS  Google Scholar 

  46. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253–9

    Article  Google Scholar 

  47. Jungmann E, Krüger K, Semler B, et al. The renoprotective effect of the converting-enzyme inhibitor ramipril in hypertensive patients with insulin-treated type 2 diabetes mellitus: dependence upon blood pressure and glycemic control [in German]. Nieren- und Hochdruckkrh 1995; 24: 248–50

    Google Scholar 

  48. Cordonnier DJ, Zaoui P, Halimi S. Role of ACE inhibitors in patients with diabetes mellitus. Drugs 2001; 61: 1883–92

    Article  PubMed  CAS  Google Scholar 

  49. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60

    Article  PubMed  CAS  Google Scholar 

  50. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9

    Article  PubMed  CAS  Google Scholar 

  51. Parving HH, Lehnert J, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–8

    Article  PubMed  CAS  Google Scholar 

  52. Lindhorm LH, Ibsen H, Dahlöf, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–10

    Article  Google Scholar 

  53. Lacourciere Y, Belanger A, Godin C, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000; 58: 762–9

    Article  PubMed  CAS  Google Scholar 

  54. Mogensen CE, Neldam S, Tikkanen, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440–4

    Article  PubMed  CAS  Google Scholar 

  55. Houlihan CA, Casley DJ, Allen TJ, et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care 2002; 25: 663–71

    Article  PubMed  CAS  Google Scholar 

  56. Rossing K, Jensen BR, Christensen PK, et al. Dual blockade of the renin-angiotensin system in diabetic nephropathy. Diabetes Care 2002; 25: 95–100

    Article  PubMed  CAS  Google Scholar 

  57. Jungmann E, Schumm-Draeger PM, Scheuermann EH, et al. Long-term antihypertensive treatment with felodipine in diabetic patients: effects on blood pressure and renal function parameters [in German]. Fortschr Med 1992; 110: 224–6

    PubMed  CAS  Google Scholar 

  58. Bretzel RG, Bollen CC, Maeser E, et al. Nephroprotective effects of nitrendipine in hypertensive type 1 and type 2 diabetic patients. Am J Kidney Dis 1993; 21Suppl. 3: 53–64

    PubMed  CAS  Google Scholar 

  59. Mosconi L, Ruggenenti P, Perna A, et al. Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. Kidney Int 1996; 49Suppl. 55: 91–3

    Google Scholar 

  60. Fogari R, Zoppi A, Corradi L, et al. Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type 2 diabetes and impaired renal function. J Hum Hypertens 1999; 13: 47–53

    Article  PubMed  CAS  Google Scholar 

  61. Jungmann E, Haak T, Schumm-Draeger PM, et al. Effect of 2-year treatment with nitrendipine vs. enalapril on urinary albumin excretion in microalbuminuric patients with type 1 diabetes mellitus [in German]. Nieren- und Hochdruckkrh 1994; 23: 38–43

    Google Scholar 

  62. Tuomiletho J, Rastenyte D, Birkenhäger WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677–84

    Article  Google Scholar 

  63. Pahor M, Psaty BM, Furberg CD. Treatment of hypertensive patients with diabetes. Lancet 1998; 351: 689–90

    Article  PubMed  CAS  Google Scholar 

  64. Stornello M, Valvo EV, Scapellato L. Comparative effects of enalapril, atenolol and chlorthalidone on blood pressure and kidney function of diabetic patients affected by arterial hypertension and persistent proteinuria. Nephron 1991; 58: 52–7

    Article  PubMed  CAS  Google Scholar 

  65. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated hypertension. JAMA 1991; 265: 3255–64

    Article  Google Scholar 

  66. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003

    Article  PubMed  Google Scholar 

  67. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA 2001; 286: 1882–5

    Article  PubMed  CAS  Google Scholar 

  68. UK Prospective Diabetes Study Group. Efficacy of atenolol and Captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713–20

    Article  Google Scholar 

  69. Ebbehoj E, Poulsen PL, Hansen KW, et al. Effects on heart rate variability of metoprolol supplementary to ongoing ACE inhibitor treatment in type 1 diabetic patients with abnormal albuminuria. Diabetologia 2002; 45: 965–75

    Article  PubMed  CAS  Google Scholar 

  70. Cohn JN, Tognoni G. A randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667–75

    Article  PubMed  CAS  Google Scholar 

  71. Gaede P, Vedel P, Parving HH, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the steno type 2 randomised study. Lancet 1999; 353: 617–22

    Article  PubMed  CAS  Google Scholar 

  72. Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002; 324: 1–5

    Google Scholar 

  73. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2002; 25Suppl. 1: S78–9

    Google Scholar 

  74. Durrington PN. Diabetic dyslipidaemia. Baillieres Best Pract Res Clin Endocrinol Metab 1999; 13: 265–78

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The author has no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

  1. St. Vincent’s Hospital Wiedenbrück, St. Vinzenz Straße 1, D-33378, Rheda-Wiedenbrück, Germany

    Eckart Jungmann

Authors
  1. Eckart Jungmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jungmann, E. Prevention and Treatment of Diabetic Nephropathy in Older Patients. Drugs Aging 20, 419–435 (2003). https://doi.org/10.2165/00002512-200320060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200320060-00002

Keywords

Search

Navigation